In today’s digital healthcare landscape, success is no longer measured purely by how many patients a platform can attract. The real challenge lies in building lasting trust while keeping patient acquisition efficient and scalable. That is exactly the strategy being executed by MedPal AI Plc (LSE:MPAL) and its newly launched consumer healthcare brand, New Health.
Speaking on The Watch List, CEO Jason Drummond outlined a clear vision for how the company intends to become a major force in the rapidly expanding GLP-1 and digital healthcare market.
A Two-Brand Strategy Built for Scale
Rather than scaling directly under the MedPal name, the company has introduced New Health as its consumer-facing platform through the premium domains new.co.uk and new.uk.
The thinking behind the move is both strategic and practical.
According to Drummond, MedPal AI serves as the regulated infrastructure powering the platform, managing AI-driven clinical workflows, pharmacy operations, clinician oversight, and prescription fulfilment. New Health, meanwhile, becomes the simple and approachable front door for consumers.
This separation allows the company to create a healthcare brand that feels accessible and trustworthy while maintaining robust medical and regulatory standards behind the scenes.
In a crowded online healthcare market, branding matters enormously. A short, memorable domain such as new.co.uk reduces friction in the patient journey, improves recall, and supports more efficient marketing performance across paid search, social media, offline campaigns, and word-of-mouth referrals.
With competitors already competing aggressively for consumer attention in the GLP-1 sector, securing premium digital real estate gives New Health a meaningful advantage.
Performance Marketing with Precision
MedPal AI is backing its expansion with a £1.3 million consumer marketing initiative focused heavily on measurable performance.
Rather than broad awareness campaigns, the investment is designed to drive highly qualified traffic to New Health and convert users into recurring patients through consultation flows, clinical assessments, and ongoing treatment support.
The company is targeting UK adults actively researching:
- Weight-loss solutions
- GLP-1 therapies
- Obesity and metabolic health
- Clinician-led online pharmacy services
Importantly, management believes the market could soon expand dramatically with the expected introduction of oral GLP-1 medications in the UK. For many consumers hesitant about injectable treatments, pill-based alternatives could significantly widen adoption and bring an entirely new audience into digital healthcare platforms.
The company’s marketing strategy is built around real-time data analysis. Key metrics include:
- Click-through rates
- Cost per click
- Consultation starts
- Completed assessments
- Conversion to paying patients
- Retention rates
- Gross contribution margins
This data-driven approach allows MedPal AI to continuously optimize spending and scale efficiently as performance improves.
Automation and Operational Leverage
One of the most compelling aspects of MedPal AI’s model is its investment in operational infrastructure.
The company has been expanding its robotic pharmacy dispensing capabilities across major fulfilment hubs, including large-scale distribution facilities totalling nearly 30,000 square feet.
As patient numbers increase, management expects automation to drive substantial operating leverage by reducing fulfilment costs while improving efficiency and scalability.
This positions the company to handle growing demand without seeing costs rise at the same pace.
Building More Than a Healthcare App
Drummond emphasized that MedPal AI is not simply building another chatbot or lead-generation platform.
Instead, the company is creating what he describes as an “operating system for personal health”, combining AI-assisted navigation, clinician-led care, prescription management, pharmacy fulfilment, and long-term patient monitoring within one integrated ecosystem.
That distinction matters.
While millions of consumers increasingly use AI tools for health-related questions, most platforms stop at providing information. MedPal AI aims to bridge the gap between digital guidance and real-world clinical care by turning those interactions into regulated treatment pathways.
Long-Term Growth Drivers
Management sees three major drivers supporting long-term margin expansion:
- Lower customer acquisition costs as brand awareness improves
- Greater efficiency through pharmacy automation and fulfilment scale
- Higher lifetime patient value through recurring treatment and ongoing care
Together, these elements create a scalable model designed for sustainable growth rather than short-term gains.
Positioned for the Future of Digital Healthcare
As consumer healthcare continues moving online, platforms that combine trusted branding, operational efficiency, and regulated medical infrastructure are likely to stand out.
With New Health providing a streamlined consumer experience and MedPal AI delivering the clinical and technological backbone behind it, the company appears well positioned to capitalize on the next phase of digital healthcare evolution.
If the GLP-1 market continues expanding, particularly with the arrival of oral therapies, MedPal AI’s strategy could prove to be a highly effective blueprint for scalable, patient-centred healthcare delivery in the UK and beyond.
For more information visit – https://www.medpal.ai/
